---
title: "Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant"
description: "Giant Biogene Holding Co. Ltd. has received approval in China for its Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, the first of its kind for intradermal injection "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272675579.md"
published_at: "2026-01-15T09:39:05.000Z"
---

# Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

> Giant Biogene Holding Co. Ltd. has received approval in China for its Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, the first of its kind for intradermal injection aimed at improving cheek smoothness. This product enhances the company's collagen portfolio and is expected to create new market opportunities in skin rejuvenation. The current analyst rating for Giant Biogene's stock (HK:2367) is a Hold with a price target of HK$39.50.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has issued an announcement.

Giant Biogene Holding Co., Ltd. announced that its wholly owned subsidiary Shaanxi Giant Biotechnology has obtained a Medical Device Registration Certificate in China for a new product, the Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, indicated for intradermal injection to improve cheek smoothness. Billed as the world’s first recombinant collagen and sodium hyaluronate composite solution implant approved for this indication, the product expands the company’s collagen-based product portfolio, reinforces its R&D and industrial capabilities, and is expected to open wider market opportunities in skin rejuvenation as the company moves ahead with commercialization efforts to strengthen its leading position in the health and beauty sector.

The most recent analyst rating on (HK:2367) stock is a Hold with a HK$39.50 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

**More about Giant Biogene Holding Co. Ltd.**

Giant Biogene Holding Co., Ltd. is a health and beauty-focused biotechnology company specializing in collagen-based medical and skincare solutions. Through subsidiaries such as Shaanxi Giant Biotechnology Co., Ltd., it develops and commercializes advanced recombinant collagen products aimed at skin rejuvenation and aesthetic treatments in the Chinese market.

**Average Trading Volume:** 11,485,053

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$37.25B

For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Giant Biogene Gains Approval for Innovative Collagen Product | Giant Biogene Holding Co. Ltd. has announced that its subsidiary, Shaanxi Giant Biotechnology Co., Ltd., received approv | [Link](https://longbridge.com/en/news/262346374.md) |
| Morgan Stanley Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367) | Morgan Stanley has maintained a Buy rating for Giant Biogene Holding Co. Ltd. with a price target of HK$42.00, while the | [Link](https://longbridge.com/en/news/270232349.md) |
| 01:24 ETKanazawa University research: Wnt signaling drives stomach cancer spread by reshaping surrounding tissue | Researchers at Kanazawa University have identified a mechanism by which gastric cancer spreads to distant organs. Their  | [Link](https://longbridge.com/en/news/276842019.md) |
| 20:31 ETCollagen Market to Grow at 7.25% CAGR Through 2031 Driven by Asia-Pacific Demand and Functional Food Applications, Says Mordor Intelligence | The collagen market is projected to grow from USD 1.42 billion in 2026 to USD 2.11 billion by 2031, with a CAGR of 7.25% | [Link](https://longbridge.com/en/news/276667431.md) |
| In HelloNation, Dermatology Expert Laurel Leithauser, MD, FFAD, FACMS Clarifies Misconceptions About Cosmetic Dermatology | In a recent article for HelloNation, Dr. Laurel Leithauser, a dermatologist from Traverse City, MI, clarifies misconcept | [Link](https://longbridge.com/en/news/276466045.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.